Reading · Thinking Kat · RSS Amplifier

This article is fourth in a Deal Screening Mastery series for emerging investors who want to build LP confidence and for early‑stage companies trying to find the right investor fit. The third article, Fund Fit, Moats, and Milestones, explores how to redefine your vision of “great idea” so founders can self‑select into your pipeline and LPs can understand your edge.

If you’ve been following this series, you have seen how the concepts of “great team” and “great idea” can be conceptualized as a set of criteria. The natural trap after developing these criteria is to create a checklist of criteria to calculate a deal value for each company, one which you can compare to a threshold number. Some people go so far as to automate that checklist as part of their deal intake form. However, a thesis is not a checklist. Rather, it is a prediction: a belief about how a specific team will create value from a specific opportunity, given the constraints and risks of the domain. Two companies can score identically on separate team and idea rubrics and represent radically different investment risks, because the interaction between this team and this idea is what determines the outcome. The jockey-versus-horse framing that dominates early-stage investing vocabulary makes this worse. It sets up a forced choice: do you bet on the people or the idea? In practice, the answer is always both, but not in the additive sense of “A-team + B-idea.” The interaction is what matters.

Recent empirical work challenges the assumption that team quality alone is the primary driver of investment decisions or outcomes. A 2025 analysis of internal VC decisions by Jang and Kaplan found that while firms were skilled at identifying teams that would gain early traction, product and market, not the founding team, were better predictors of sustained long-term growth. This suggests that investors who over-weight team at the expense of idea quality may be systematically missing the best outcomes.[1] The data from actual deal memos is even more instructive. Analysis of 162 real VC deal memos from 2026 found that “conviction” — the integrated, gut-level “this is a winner” signal — was the #1 predictor of investment enthusiasm (r=0.598), ahead of traction (r=0.544) and well ahead of team (r=0.328) as an isolated variable. In healthcare specifically, market and product dominate the evaluation signal (r=0.916 and r=0.923 respectively), while team alone barely registers (r=0.503). In this dataset, team-first deals average lower overall scores (7.64) than multi-thesis deals (7.93), which check multiple boxes simultaneously.[2] These findings don’t diminish the importance of team evaluation. They reframe it: team quality matters most when it is assessed in relationship to the idea, not as a standalone variable. The signal that distinguishes a fundable deal emerges from the coherent story of team-meets-idea, not from scoring each separately and hoping they add up.

The concept that bridges team and idea most usefully in life sciences is Founder-Problem Fit (FPF): the founder’s unique connection to the specific problem the company is trying to solve, rooted in lived experience, domain literacy, and insight.[3] FPF is distinct from both “great team” and “great idea” as standalone concepts. This framework asks, “Why is this person the right one to solve this problem, and what evidence exists that their background, networks, and mental models are calibrated to the specific execution risks this idea faces”? In practice, strong FPF manifests as three observable patterns:

The founder has deep domain literacy, speaking the language of customer pain, regulatory constraints, and operational realities in their target environment, not just the investor narrative about it.
A track record of meaningful problem-solving in the same market or closely adjacent spaces. This is not necessarily prior exits, but demonstrable evidence of having operated in the system they’re trying to change.
A credible, testable path to product-market fit that is supported by customer validation, pilot outcomes, or early evidence.

In life sciences, FPF is particularly high-stakes because the execution risks are domain-specific in ways that general business skills cannot offset. A founder without regulatory literacy who is building a platform that requires a de novo FDA pathway is not a “great team” missing one skill; instead, they are a team-idea mismatch. The same founder attacking a real-world evidence software product with an existing regulatory framework is a completely different risk profile, even if their credential sheet looks identical.[4]

Thanks for reading Thinking Kat! If you found this issue valuable, please pass it to someone else who would benefit.

Share Thinking Kat

Even though we risk making FPF into just another scoring system, it’s useful to break the concept down into four questions that explore the depth of the relationship.

The strongest signal of FPF is insight origin. The question is “does the founding team’s direct experience explain why they saw this opportunity before anyone else did?” If the insight cannot be traced to a credible origin in the team’s lived experience, either the insight isn’t as original as claimed, or the team didn’t generate it, and both are red flags. A founder who lived the problem is more likely to correctly identify the actual barrier to adoption, design experiments around the right hypotheses, and maintain conviction through the inevitable setbacks in development. Critically, and contravening some popular investment advice, this is not about pedigree. First-time founders can have stronger FPF than repeat founders if their domain proximity is more direct and recent.

Every idea in life sciences faces one or more execution risks at screening: scientific/technical, clinical, commercial/reimbursement, or operational. A coherent thesis requires that the team’s deepest capability addresses the primary risk the idea faces at its current stage, not the risks they would face three stages from now. A team of brilliant scientists attacking a company whose primary risk is a complex payer contracting structure is a mismatch. This is the best point for evaluating the advisory bench. Advisors serve their function when they specifically bridge the gap between the team’s primary capability and the idea’s primary risk. A long list of prestigious advisors that doesn’t address the execution-critical gap is noise. Two targeted advisors who directly de-risk the critical path are a meaningful signal.

In an earlier article, we established the importance of understanding why this problem is solvable now as a screening criterion. The “why now” insight is generally due to a specific structural change that is not common knowledge, including a policy shift, an enabling technology, a cost curve inflection, or a guideline update. A team that owns the “why now” insight has been tracking the underlying structural change long enough to understand its second-order implications. They can describe not just what changed, but what that means for product adoption in specific settings. They have skin in the timing, because their professional lives positioned them to notice it first. A team that cannot articulate “why now” beyond sector-level platitudes (”AI is transforming healthcare,” “there’s an unmet need in rare disease”) is likely appropriating an idea rather than originating one.

Structural defensibility is what makes an idea hard to copy: regulatory complexity, channel relationships, long-cycle trust assets, or switching barriers. This question is about whether the team’s expertise creates that moat or merely benefits from it passively. The distinction matters because moats built on expertise are actively maintained while moats built on a one-time technical advantage erode. A team of deep regulatory experts building a platform that requires sophisticated FDA strategy is creating a defensibility moat through their own knowledge density (if they stay with the company). The same platform built by a team that hired their way into regulatory expertise or borrowed it from advisors has a structurally weaker moat, because the key capability can walk out the door or is available to competitors.

I see many examples of FPF mismatch in my work. Here are some common situations:

The research team in a commercial setting – domain experts (scientists, clinicians, academics) attacking a problem whose primary risk is commercial rather than scientific. The FPF is high on domain alignment but low on risk-capability match.
The platform in search of a specific foothold - a technically sophisticated team building a platform they believe will transform a healthcare workflow, but with no specific, deep understanding of one buyer, one workflow, or one proof point. The answers to each of the FPF questions are unsatisfactory. I’ve frequently seen this situation emerge when tech founders attempt to transition to a healthtech domain based on perceived market size and their technical execution capability.
The capability gap at the wrong stage – the team skills match the idea perfectly at formation but are not equipped for the next stage. The FPF may be high at first; however, an inability to adapt can slow or block progress. Founders who are unable recognize the need for new expertise are a common source of stage disruption due to capability gaps.
The insight or moat are borrowed - an idea is credible because it was originated by someone else; the moat exists because the team has relationships they didn’t earn. The FPF is low if the founders can’t explain the insight as if they discovered it or defend the moat without referencing their advisors.

Once you have answered the FPF questions, the next step is condensing them into a 2-4 sentence thesis statement for the company. That can be as simple as putting the answers into this template:

We are investing because this founding team has [a distinctive team capability] which gives them direct insight into [the specific idea that creates the opportunity] and [the connection mechanism] that makes them the right people at the right time to solve [the problem]. The primary risk we are betting against is [what would have to be true for this investment to fail].

VC Lab describes this as the “Bet” — what wager are you making about the world?[5] Formulating this sentence is an early step in the deal memo you will eventually write. It shares the basic logic about the investment in a way that can be tested and shared with your investing thought partners and as part of LP communications. Both the FPF questions and the thesis statement give you elements of concrete feedback for companies in your deal flow, especially those you’d like to see again if they can correct their weaknesses. It’s also a dynamic prediction, which can and should change with team, situation, and risk evolution. Documenting an evolving thesis statement is how team and idea evaluation remain integrated over the life of the investment, rather than diverging into separate portfolio management conversations.

I’m not saying that a screening process using independent criteria for the team and the idea is wrong. Instead, I’m noting that an integrative framework like FPF lets you triage your deal flow using high-value signals that combine into a single statement of rationale. Companies that should enter due diligence will be more obvious, and those needing improvement can receive meaningful feedback, thereby building trust. These company-level thesis statements also bring your fund investment thesis into sharper focus for your LPs, another trust-building move. Because isn’t venture funding, at its heart, a trust relationship?

I’m percolating a few ideas for the next Deal Screening Mastery article, and I welcome your ideas and criticism of earlier installments. DM me on LinkedIn with your thoughts, and make sure to include “Deal Screening Mastery feedback” in your message. Or leave a comment below!

Deal Screening Mastery (Part 4 of 12): Founder-Problem Fit

Comments